Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects.
Gootz
T D
TD
Department of Cancer, Immunology, and Infectious Diseases, Pfizer Inc., Groton, Connecticut 06340, USA.
Brighty
K E
KE
D000818:Animals; D000890:Anti-Infective Agents / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001421:Bacteria, Anaerobic / Q000187:drug effects; D004352:Drug Resistance, Microbial; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D011355:Prodrugs; D013329:Structure-Activity Relationship
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D011355:Prodrugs